Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Ibrutinib (Primary) ; SD 101 Dynavax (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2016 Planned primary completion date changed from 1 Aug 2021 to 1 Nov 2021.
- 29 Nov 2016 Status changed from not yet recruiting to recruiting.
- 12 Oct 2016 New trial record